Ligand validation:6TVD

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 6TVD designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6TVD_NAG_G_404	63%	61%	0.122	0.916	0.46	1.01	-	1	1	0	100%	0.9333
6TVD_NAG_C_401	58%	67%	0.142	0.919	0.46	0.8	-	1	0	0	100%	0.9333
6TVD_NAG_B_201	56%	55%	0.161	0.932	0.44	1.29	-	3	0	0	100%	0.9333
6TVD_NAG_K_401	35%	60%	0.175	0.864	0.49	1.02	-	1	0	0	100%	0.9333
6TVD_NAG_I_403	33%	59%	0.2	0.878	0.43	1.13	-	1	0	0	100%	0.9333
6TVD_NAG_E_401	27%	56%	0.25	0.9	0.33	1.34	-	3	0	0	100%	0.9333
6TVD_NAG_A_404	23%	46%	0.222	0.844	0.59	1.47	-	3	0	0	100%	0.9333
6TVD_NAG_L_203	17%	59%	0.235	0.812	0.44	1.12	-	2	0	0	100%	0.9333
6TVD_NAG_F_203	8%	52%	0.19	0.669	0.68	1.17	1	2	1	0	100%	0.9333
4QY2_NAG_J_601	77%	75%	0.099	0.937	0.44	0.55	-	-	0	0	100%	0.9333
4QY1_NAG_D_601	77%	85%	0.109	0.947	0.3	0.44	-	-	1	0	100%	0.9333
4WSX_NAG_K_401	76%	21%	0.097	0.933	0.46	2.78	-	3	0	0	100%	0.9333
4QY0_NAG_J_601	68%	79%	0.132	0.945	0.35	0.51	-	-	0	0	100%	0.9333
6TWV_NAG_J_201	68%	48%	0.115	0.925	0.33	1.66	-	1	0	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5F9W_NAG_A_510	100%	88%	0.023	0.994	0.24	0.43	-	-	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.